Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lifted by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 58.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,266 shares of the company's stock after acquiring an additional 5,989 shares during the quarter. J.W. Cole Advisors Inc.'s holdings in Novo Nordisk A/S were worth $1,129,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL grew its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after buying an additional 300 shares in the last quarter. Copeland Capital Management LLC raised its position in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. bought a new position in Novo Nordisk A/S in the 1st quarter valued at $27,000. Park Square Financial Group LLC purchased a new position in Novo Nordisk A/S in the 4th quarter worth about $29,000. Finally, Transce3nd LLC bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $33,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded up $0.71 on Thursday, hitting $70.74. The stock had a trading volume of 10,157,270 shares, compared to its average volume of 7,044,014. The company's 50 day moving average price is $70.52 and its 200 day moving average price is $73.88. The stock has a market cap of $315.84 billion, a price-to-earnings ratio of 20.93, a P/E/G ratio of 1.35 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. The company had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Analysts Set New Price Targets

NVO has been the topic of a number of recent analyst reports. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Dbs Bank downgraded Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating on the stock. BMO Capital Markets reaffirmed a "market perform" rating and issued a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.